Molecular modeling of wild-type and D816V c-kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases

Journal of Medicinal Chemistry

Volumn 48, Issue 20, 2005, Pages 6194-6201

  Vendôme, Jérémie ^a   Letard, Sébastien ^b   Martin, Frédéric ^a   Svinarchuk, Fedor ^a   Dubreuil, Patrice ^b   Auclair, Christian ^a   Le Bret, Marc ^a  

^a Ecole Normale Superieure de Cachan   (France)

^b Lab 'Rythmes Biologiques C   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5,11 DIMETHYL 6H PYRIDO[3,4 B]CARBAZOLE; ADENOSINE TRIPHOSPHATE; ELLIPTICINE DERIVATIVE; IMATINIB; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; MASTOCYTOSIS; MOLECULAR DYNAMICS; POINT MUTATION; PROTEIN DOMAIN; WILD TYPE;

EID: 26444598487     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050231m     Document Type: Article

References (32)

1. Sehlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103, 211-225.
2. Hunter, T. Signaling- -2000 and beyond. Cell 2000, 100, 113-127.
3. d mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo. Am. J. Pathol. 1987, 127, 191-198.
4. Galli, S. J.; Zsebo, K. M.; Geissler, E. N. The kit ligand, stem cell factor. Adv. Immunol. 1994, 55, 1-96.
5. Weiss, A.; Schlessinger, J. Switching signals on or off by receptor dimerization. Cell 1998, 94, 277-280.
6. Huse, M.; Kuriyan, J. The conformational plasticity of protein kinases. Cell 2002, 109, 275-282.
7. Mol, C. D.; Lim, K. B.; Sridhar, V.; Zou, H.; Chien, E. Y.; Sang, B. C.; Nowakowski, J.; Kassel, D. B.; Cronin, C. N.; McRee, D. E. Structure of a c-kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 2003, 278, 31461-31464.
8. Lemmon, M. A.; Ferguson, K. M.; O'Brien, R.; Sigler, P. S.; Schlessinger, J. Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain. Proc. Natl. Acad. Sci. U.S.A. 1995, 97, 10472-10476.
9. Ma, Y.; Longley, B. J.; Wang, X.; Blount, J. L.; Langley, K.; Caughey, G. H. Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. J. Invest. Dermatol. 1999, 112, 165-170.
10. Furitsu, T.; Tsujimura, T.; Tono, T.; Ikeda, H.; Kitayama, H.; Koshimizu, U.; Sugahara, H.; Butterfield, J. H.; Ashman, L. K.; Kanayama, Y.; et al. Identification of mutations in the coding sequence of the proto-oncogene c-Kit in a human mast cell leukemia cell line causing a ligand-independent activation of c-Kit product. J. Clin. Invest. 1993, 92, 1736-1744.
11. Hirota, S.; Isozaki, K.; Moriyama, Y.; Hashimoto, K.; Nishida, T.; Ishiguro, S.; Kawano, K.; Hanada, K.; Kurata, A.; Takeda, M.; Muhammad Tunio, G.; Matsuzawa, Y.; Kanakura, Y.; Shinomura, Y.; Kitamura, Y. Gain-of-function mutations of c-Kit in human gastrointestinal tumors. Science 1998, 279, 577-580.
12. Liao, A. T.; Chien, M. B.; Shenoy, N.; Mendel, D. B.; McMahon, G.; Cherrington, J. M.; London, C. A. Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors. Blood 2002, 100, 585-593.
13. Tsujimura, T.; Furitsu, T.; Morimoto, M.; Isozaki, K.; Nomura, S.; Matsuzawa, Y.; Kitamura, Y.; Kanakura, Y. Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation. Blood 1994, 83, 2619-2626.
14. Nagata, H.; Okada, T.; Worobec, A. S.; Semere, T.; Metcalfe, D. D. c-Kit mutation in a population of patients with mastocytosis. Int. Arch. Allergy Immunol. 1997, 113, 184-186.
15. Ma, Y.; Zeng, S.; Metcalfe, D. D.; Akin, C.; Dimitrijevic, S.; Butterfield, J. H.; McMahon, G.; Longley, B. J. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002, 99, 1741-1744.
16. Zermati, Y.; De Sepulveda, P.; Feger, F.; Letard, S.; Kersual, J.; Casteran, N.; Gorochov, G.; Dy, M.; Ribadeau Dumas, A.; Dorgham, K.; Prizot, C.; Bieche, Y.; Vidaud, M.; Hermine, O.; Dubreuil, P. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-Kit receptors found in mast cell neoplasms. Oncogene 2003, 22, 660-664.
17. Ma, Y.; Carter, E.; Wang, X.; Shu, C.; McMahon, G.; Longley, B. J. Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells. J. Invest. Dermatol. 2000, 114, 392-394.
18. Longley, B. J.; Reguera, M. J.; Ma, Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res. 2001, 25, 571-576.
19. Le Pecq, J. B.; Nguyen-Dat-Xuong, X.; Gossi, C.; Paoletti, C. A new antitumoral agent: 9-hydroxyellipticine. Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs. Proc. Natl. Acad. Sci. U.S.A. 1974, 71, 5078-5082.
20. Kohn, K. W.; Waring, M. J.; Glaubiger, D.; Friedman, C. A. Intercalative binding of ellipticine to DNA. Cancer Res. 1975, 35, 71-76.
21. Zwelling, L. A.; Michaels, S.; Kerrigan, D.; Pommier, Y.; Kohn, K. W. Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium. Biochem. Pharmacol. 1982, 31, 3261-3267.
22. Tewey, K. M.; Chen, G. L.; Nelson, E. M.; Liu, L. F. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 1984, 259, 9182-9187.
23. Fosse, P.; Rene, B.; Le Bret, M.; Paoletti, C.; Saucier, J. M. Sequence requirements for mammalian topoisomerase II mediated DNA cleavage stimulated by an ellipticine derivative. Nucleic Acids Res. 1991, 19, 2861-2868.
24. Kim, M. S.; Blake, M.; Baek, J. H.; Kohlhagen, G.; Pommier, Y.; Carrier, F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res. 2003, 63, 7291-7300.
25. De Marini, D. M.; Abu-Shakra, A.; Gupta, R.; Hendee, L. J.; Levine, J. G. Molecular analysis of mutations induced by the intercalating agent ellipticine at the hisD3052 allele of Salmonella typhimurium TA98. Environ. Mol. Mutagen. 1992, 20, 12-18.
26. Stiborova, M.; Breuer, A.; Aimova, D.; Stiborova-Rupertova, M.; Wiessler, M.; Frei, E. DNA adduct formation by the anticancer drug ellipticine in rats determined by 32P postlabeling. Int. J. Cancer 2003, 107, 885-890.
27. Mol, C. D.; Dougan, D. R.; Schneider, T. R.; Skene, R. J.; Kraus, M. L.; Scheibe, D. N.; Snell, G. P.; Zou, H.; Sang, B. C.; Wilson, K. P. Structural basis for the autoinhibition and STI-571 inhibition of c-kit tyrosine kinase. J. Biol. Chem. 2004, 279, 31655-31663.
28. Auclair, C.; Pierre, A.; Voisin, E.; Pepin, O.; Cros, S.; Colas, C.; Saucier, J. M.; Vershuere, B.; Gros, B.; Paoletti, C. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxy ellipticinium-chloride, HCl. Cancer Res. 1987, 47, 6254-6261.
29. Larue, L.; Rivalle, C.; Muzard, G.; Paoletti, C.; Bisagni, E.; Paoletti, J. A new series of ellipticine derivatives (1-(alkylamino)-9-methoxyellipticine) . Synthesis, DNA binding, and biological properties. J. Med. Chem. 1988, 31, 1951-1956.
30. Berendsen, H. J. C.; Van der Spoel, D.; and Van Drunen, R. GROMACS: a message-passing parallel molecular dynamics implementation. Comput. Phys. Commun. 1995, 91, 43-56.
31. Lindahl, E.; Hess, B.; Van der Spoel, D. GROMACS: a package for molecular simulation and trajectory analysis. J. Mol. Model. 2001, 7, 306-317.
32. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 1980, 36, 3219-3228.